Please login to the form below

Not currently logged in
Email:
Password:

Grünenthal's Harald Stock joins OvaScience board

Provides European expertise as fertility company looks to expand beyond US

Harald Stock, OvaScienceInfertility specialist OvaScience has appointed Harald Stock, CEO of German pharma firm Grünenthal, to its board of directors.

Stock, who has served in his position at Grünenthal since 2009, will provide US-based OvaScience with strong working knowledge of the European pharma market as the company looks to expand its global reach.

“The global fertility market is nearly 10 times larger than the US alone, and growing rapidly,” said Dr Michelle Dipp, CEO of OvaScience.

“Harald's expertise and success commercialising products in global healthcare markets will be important to OvaScience as we advance our ex-US strategy.”

Prior to joining Grünenthal, Stock was chairman and managing director of the German DePuy Group, the orthopaedics division of Johnson & Johnson.

He has also spent time with Roche, serving in a variety of senior positions, including senior VP of its  global near patient testing business.

In addition, Stock is a board member of EFPIA and previously represented J&J on the board of BVMed, the body representing the medical technology industry in Germany.

12th February 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....